Nalgesin Mini, 220 mg, coated tablets
naproxen sodium
This medicine should always be taken exactly as described in the patient leaflet or as directed by your doctor, pharmacist, or nurse.
Nalgesin Mini is a pain-relieving medicine that reduces inflammation.
The medicine works by inhibiting the synthesis of prostaglandins. The pain-relieving effect occurs quickly
and lasts for up to 12 hours.
Nalgesin Mini is indicated for short-term treatment of mild to moderate pain, such as: headache, toothache, painful menstruation, joint pain,
muscle pain.
If after 3 days there is no improvement or you feel worse, you must contact your doctor.
General
The frequency of side effects is dependent on the dose and duration of treatment. You should always use the smallest effective dose of Nalgesin Mini for the shortest time necessary to relieve pain.
You should avoid taking naproxen sodium at the same time as other NSAIDs (including selective COX-2 inhibitors).
During long-term use of naproxen sodium, it is necessary to check liver and kidney function, especially in patients with liver or kidney problems, heart disease, or those taking diuretics, as well as in patients over 65 years old.
You should discuss the use of Nalgesin Mini with your doctor or pharmacist before starting treatment.
Gastrointestinal effects
Bleeding, ulcers, or perforations of the gastrointestinal tract, which can be fatal, have been reported with all NSAIDs, at any time during treatment, with or without warning symptoms.
The risk of bleeding, ulcers, or perforation of the gastrointestinal tract increases with higher doses of NSAIDs in patients who have had ulcers before and in the elderly. Treatment should be started with the lowest available dose.
Patient with a history of toxic effects on the gastrointestinal tract, especially the elderly, are advised to report any disturbing abdominal symptoms (especially gastrointestinal bleeding) to their doctor.
Concomitant use of medications used to treat pain and inflammation (corticosteroids), anticoagulant medications (warfarin), selective serotonin reuptake inhibitors, or antiplatelet agents, such as aspirin (see section 4.5), may increase the risk of gastrointestinal ulcers or bleeding.
Effects on the cardiovascular and cerebrovascular systems
Medicines like Nalgesin Mini may slightly increase the risk of heart attack (myocardial infarction) or stroke. This risk is higher in patients taking high doses or undergoing long-term treatment. You should not exceed the recommended dose or duration of treatment.
Patient with heart disease, who have had a stroke, or are suspected to be at increased risk of these conditions (e.g., patients with high blood pressure, diabetes, or high cholesterol, or smokers) should discuss their treatment with their doctor or pharmacist.
Skin reactions
Serious skin reactions, including fatal ones, have been very rarely reported, especially during the initial stages of therapy with NSAIDs. If you notice any rash, itching, mucosal lesions, or other signs of allergy/hypersensitivity, you should stop taking the medicine and consult your doctor.
Hypersensitivity reactions
Serious allergic reactions have been very rarely reported. Patients with a history of facial and throat swelling, any allergy, asthma, chronic nasal inflammation, or chronic respiratory disease are more prone to serious hypersensitivity reactions.
In case of the first symptoms of a serious allergic reaction, you should stop taking the medicine.
Fertility precautions
This medicine belongs to a group of medicines (NSAIDs) that may have a negative effect on female fertility. This effect is reversible after stopping the medicine.
Nalgesin Mini should not be used in children under 16 years of age.
You should tell your doctor or pharmacist about all the medicines you are taking or have recently taken, as well as any medicines you plan to take.
As a result of interactions with some other medicines, the effect of Nalgesin Mini or the effect of these medicines may be increased or decreased. This is the case with:
Tablets should be swallowed with a sufficient amount of liquid, preferably during a meal.
You should not consume alcohol while taking naproxen sodium, as alcohol may increase the risk of gastrointestinal bleeding associated with NSAIDs.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before taking this medicine.
Nalgesin Mini should not be used during the last three months of pregnancy, as it may harm the unborn child or cause problems during delivery. This may cause kidney and heart problems in the unborn child, as well as affect the tendency to bleeding in the mother and child, and delay or prolong delivery. You should not take Nalgesin Mini during the first six months of pregnancy, unless it is absolutely necessary and recommended by your doctor.
If treatment is necessary during this period or while trying to conceive, you should use the smallest dose for the shortest time possible. From the 20th week of pregnancy, Nalgesin Mini may cause kidney problems in the unborn child if taken for more than a few days.
This may lead to a decrease in the amount of amniotic fluid surrounding the baby (oligohydramnios).
If treatment is necessary for a longer period than a few days, your doctor may recommend additional monitoring.
You should not breastfeed while taking Nalgesin Mini.
Nalgesin Mini has no or negligible influence on the ability to drive and use machines. Dizziness, drowsiness, fatigue, and vision disturbances are possible side effects of NSAIDs. If you experience such symptoms, you should not drive or operate machinery.
Nalgesin Mini contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, so it can be considered "sodium-free".
This medicine should always be taken exactly as directed by your doctor or pharmacist. If you are unsure, you should talk to your doctor or pharmacist.
The recommended dose for adults and adolescents over 16 years old with a weight over 50 kg is 1 tablet every 8-12 hours.
Alternatively, you can take two tablets at once and, if necessary, one additional tablet after 8-12 hours.
Tablets should be swallowed with a sufficient amount of liquid, during or after a meal.
In patients with stomach sensitivity, it is beneficial to take the medicine during a meal. Tablets should not be chewed.
The maximum daily dose is 3 tablets (equivalent to 660 mg of naproxen sodium).
You should not take Nalgesin Mini for more than 7 days. If after 3 days of treatment the pain persists, and if the symptoms worsen, you should consult your doctor.
The dosage for children over 16 years old with a weight over 50 kg is the same as for adults.
Nalgesin Mini is not intended for use in children and adolescents under 16 years of age.
The maximum recommended daily dose of Nalgesin Mini is 2 tablets divided into two doses.
You should use the smallest effective dose.
The maximum recommended daily dose of Nalgesin Mini is 2 tablets divided into two doses.
You should use the smallest effective dose.
You should not take Nalgesin Mini if you have severe renal impairment (see "When not to take Nalgesin Mini").
The maximum recommended daily dose of Nalgesin Mini is 2 tablets divided into two doses.
You should use the smallest effective dose.
You should not take Nalgesin Mini if you have severe liver impairment (see "When not to take Nalgesin Mini").
Overdose may cause stomach pain, nausea, vomiting, dizziness, ringing in the ears, irritability, and in severe cases, bleeding vomiting, black stools, disturbances of consciousness, breathing difficulties, seizures, and kidney failure.
If you think that the effect of Nalgesin Mini is too strong or too weak, you should talk to your doctor or pharmacist.
You should not take a double dose to make up for a missed dose.
During short-term use of naproxen sodium to relieve pain, you can safely stop taking the medicine if it is no longer needed.
If you have any further doubts about the use of this medicine, you should talk to your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Very rare (may affect up to 1 in 10,000 people):
Frequency not known(frequency cannot be estimated from the available data):
Nalgesin Mini may slightly increase the risk of heart attack (myocardial infarction) or stroke.
You should stop taking Nalgesin Mini immediately and consult your doctor if you experience any of the following symptoms:
If you experience any side effects, including those not listed in the leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Do not store above 25°C.
Store in the original packaging to protect from light.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Coated tablets; oval, slightly convex on both sides, light blue-gray with a metallic sheen: tablet thickness: 4.2 mm - 4.6 mm, tablet length: 13.5 mm - 13.8 mm.
Packaging: 10, 20, or 30 tablets in PVC/Aluminum blisters, in a cardboard box.
Not all pack sizes may be marketed.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Country name | Medicine name |
Portugal | Neuredon 200 mg film-coated tablets |
Hungary | ANalgesin Dolo 220 mg film-coated tablets |
Lithuania | Nalgedol 220 mg coated tablets |
Romania | Naldorex |
Austria | Nalgesin 200 mg Rapid film-coated tablets |
Finland | Nalgesin One |
Date of last revision of the leaflet:08.08.2024
Detailed information on this medicine can be found on the website of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products http://urpl.gov.pl
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.